[A17-20] Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2017
Commission awarded on 02.05.2017 by the Federal Joint Committee (G-BA).
Advanced NSCLC (lung cancer) with T790M mutation after pretreatment with EGFR-TKI
Hint for non-quantifiable, at least considerable added benefit versus cisplatin + pemetrexed
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A18-45||Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A17-47||Osimertinib (lung cancer) - Addendum to Commission A17-20||Commission completed|
|A16-14||Osimertinib - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A21-86||Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2017-10-19 A G-BA decision was published.